Anticancer research 2017 Jan
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer.
ABSTRACT
AIM
To assess the role of stereotactic body radiotherapy (SBRT) in pulmonary metastases from colorectal cancer (CRC).
PATIENTS AND METHODS
Thirty-three consecutive patients with pulmonary metastases from CRC who received SBRT were included in the analysis. The primary endpoints were local and systemic progression-free survival, a secondary endpoint was the safety profile of SBRT.
RESULTS
A total of 56 lesions were treated with SBRT. A single nodule was treated in 15 patients, two in 13 and three in five. The radiotherapy dose and the adopted fractionations were 24-27 Gy as a single fraction for 40 lesions and 27-42 Gy in three fractions (2-3 times a week) for the other 16 lesions. After a median follow-up of 22.8 months (range=1.3-45.7 months), the median progression-free survival of the irradiated sites was 13.4 months.
CONCLUSION
SBRT can be considered as local therapy in patients with lung metastases from CRC.
Related Questions
No disease elsewhere. Previous history of treated rectal cancer a few years ago.
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (June 16, 2024)
This question brings other considerations such as oligometastatic versus oligoprogressive disease, radioresistant versus radiosensitive primary cancer, as well as biologically...